BioSpace News Archive

NuLiv Science, a leading plant-based nutraceutical ingredients company enabling people to lead healthier lives, announced the release of a study examining the efficacy and safety of Verbasnol™ (Rehmannia glutinosa Libosch leaf-based extract (RGLE)) for moderate to severe acne in females.

The global D-dimer testing market is set to witness a rapid rise in revenue from US$ 1,500.27 million in 2023 to US$ 2,269.31 million by 2032.

New funding enables healthŌme to enhance its genomics-based precision health offerings in the life and critical illness insurance sectors.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Medical Officer Dr. Raj Malik and Chief Commercial Officer Andrew Perry will participate in a fireside chat at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on Wednesday, May 29, at 8:30AM EDT.

Enzolytics, Inc. announced today that it has entered into a Letter of Intent with Enogenesis (ENGN) for the specific use of the therapeutic application of ENGN’s patented Nitric Oxide Compound.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced the presentation of additional preclinical data for KT-621, a potent, selective, oral heterobifunctional degrader of STAT6, at the American Thoracic Society (ATS) Annual Meeting in San Diego, California.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, announced the results of the Combined Shareholders Meeting which took place on May 22, 2024.

Immunis, Inc., a clinical-stage biotech developing innovative secretome therapies to address age-related disease and immune dysfunction, obtained a significant strategic milestone in partnering with Toray, a Japanese drug company part of the Toray Group.

It is a New Day for Norepinephrine! Long Grove Pharmaceuticals now offers ready-to-use Norepinephrine in 0.9% Sodium Chloride in the 16 mg/250mL (64 mcg/mL) strength and anticipates the availability of the 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) strengths in early summer.

Sen-Jam Pharmaceutical, a leading innovator in the development of therapeutics for age-related diseases, is pleased to announce the upcoming completion of the clinical trial for its groundbreaking therapeutic, SJP-002C, in July 2024.